公开(公告)号：US20120295814A1

公开(公告)日：2012-11-22

申请号：US13520665

申请日：2011-01-07

申请人： Daniel Cramer ,  Brian Liu ,  Dennis O'Rourke

发明人： Daniel Cramer ,  Brian Liu ,  Dennis O'Rourke

IPC分类号： G01N33/574 ,  G01N33/577 ,  C40B30/04

CPC分类号： C07K16/3092 ,  G01N33/57449 ,  G01N2800/50 ,  G01N2800/54

摘要： The invention is directed to assays of CA-125 immune complexes that can be used diagnostically. It also includes glass or plastic plates or slides on which the monoclonal antibodies against CA-125 have been immobilized and kits containing these plates or slides.

摘要翻译： 本发明涉及可以在诊断上使用的CA-125免疫复合物的测定。 它还包括玻璃或塑料板或载玻片，抗CA-125的单克隆抗体已经固定在其上，并含有这些板或载玻片的试剂盒。

公开(公告)号：US08642347B2

公开(公告)日：2014-02-04

申请号：US12865508

申请日：2009-01-30

申请人： Bin Ye ,  Daniel Cramer

发明人： Bin Ye ,  Daniel Cramer

IPC分类号： G01N33/574 ,  G01N33/53 ,  G01N33/00 ,  C12P21/04 ,  A61K38/00 ,  C07K1/00

CPC分类号： G01N33/57449 ,  C07K14/4748

摘要： The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.

摘要翻译： 本发明涉及基于检测衍生自CA125降解的肽的诊断方法。 特别地，它涉及从妇女收集的尿液样品的测定，以确定它们是否具有增加的患有卵巢癌的风险，降低其作为临床或非临床程序的结果的风险，以监测其功效 治疗方法，或确定癌症是否复发或进展。

公开(公告)号：US20050009120A1

公开(公告)日：2005-01-13

申请号：US10869027

申请日：2004-06-17

申请人： Samuel Mok ,  Bin Ye ,  Daniel Cramer

发明人： Samuel Mok ,  Bin Ye ,  Daniel Cramer

IPC分类号： G01N33/574 ,  C07H21/04

CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/112 ,  G01N33/57449

摘要： The present invention is directed to diagnostic methods based upon the expression of the protein osteopontin. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer.

摘要翻译： 本发明涉及基于蛋白质骨桥蛋白表达的诊断方法。 特别地，它涉及从妇女收集的尿液样品的测定，以确定它们是否具有增加患有卵巢癌的风险。

公开(公告)号：US20150362497A1

公开(公告)日：2015-12-17

申请号：US14763492

申请日：2014-01-30

申请人： Karen ANDERSON ,  Joshua LABAER ,  Garrick WALLSTROM ,  Daniel CRAMER ,  ARIZONA BOARD OF REGENTS, A BODY CORPRATE OF THE S TATE OF ARIZONA, ACTING FOR AND BEHALF OF ARI

发明人： Karen Anderson ,  Joshua LaBaer ,  Garrick Wallstrom ,  Daniel Cramer

IPC分类号： G01N33/574

CPC分类号： G01N33/57488 ,  G01N33/57449 ,  G01N2333/471 ,  G01N2333/4748 ,  G01N2333/5756 ,  G01N2333/90666 ,  G01N2333/914 ,  G01N2800/7028

摘要： Methods for identifying antigens as potential biomarkers for the early detection of ovarian cancer, as well as kits for utilizing said antigens as biomarkers and in personalized medicine/therapeutics assessment. Protein microarrays displaying full-length candidate antigens were developed and sequentially screening to select candidate autoantibody biomarkers to limit the false discovery rate inherent to large-scale proteomic screening.

摘要翻译： 将抗原识别为用于早期检测卵巢癌的潜在生物标志物的方法，以及用于利用所述抗原作为生物标志物和个性化医学/治疗学评估的试剂盒。 开发显示全长候选抗原的蛋白质微阵列，并依次筛选选择候选自身抗体生物标志物，以限制大规模蛋白质组学筛选固有的假发现率。

公开(公告)号：US20090099102A1

公开(公告)日：2009-04-16

申请号：US12084122

申请日：2006-10-24

申请人： Bin Ye ,  Daniel Cramer

发明人： Bin Ye ,  Daniel Cramer

IPC分类号： A61K31/7028 ,  A61K31/343 ,  A61P35/00

CPC分类号： A61K36/16 ,  A61K31/366

摘要： The present invention is directed to pharmaceutical compositions and nutritional supplements that contain large amount of ginkgolides, particularly ginkgolide A or B, and for which, the other components normally found in Ginkgo biloba extracts have been removed. The compositions may be administered to women to prevent or treat ovarian cancer, particularly non-mucinous ovarian cancer.

摘要翻译： 本发明涉及含有大量银杏内酯，特别是银杏内酯A或B的药物组合物和营养补充剂，并且其中通常存在于银杏叶提取物中的其它组分已被除去。 可以将组合物施用于妇女以预防或治疗卵巢癌，特别是非粘液性卵巢癌。

公开(公告)号：US20110045508A1

公开(公告)日：2011-02-24

申请号：US12865508

申请日：2009-01-30

申请人： Bin Ye ,  Daniel Cramer

发明人： Bin Ye ,  Daniel Cramer

IPC分类号： G01N33/68 ,  C12P21/00

CPC分类号： G01N33/57449 ,  C07K14/4748

摘要： The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.

摘要翻译： 本发明涉及基于检测衍生自CA125降解的肽的诊断方法。 特别地，它涉及从妇女收集的尿液样品的测定，以确定它们是否具有增加的患有卵巢癌的风险，降低其作为临床或非临床程序的结果的风险，以监测其功效 治疗方法，或确定癌症是否复发或进展。

公开(公告)号：US20190302122A1

公开(公告)日：2019-10-03

申请号：US16317184

申请日：2017-07-11

申请人： Benjamin KATCHMAN ,  Karen ANDERSON ,  Garrick WALLSTROM ,  Joshua LABAER ,  Daniel CRAMER ,  ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Benjamin Katchman ,  Karen Anderson ,  Garrick Wallstrom ,  Joshua LaBaer ,  Daniel Cramer

IPC分类号： G01N33/574

摘要： Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.